Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 5Neoplasm Metastasis 2NSCLC 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Non-small Cell Lung Cancer Metastatic 1Brain Neoplasms 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × dacomitinib × Thoracic × Clear all
NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Peking Union Medical College

Unknown
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡